Even As PBMs Face Reckoning, Formulary Exclusions Rise Again In 2023
Congressional scrutiny aside, ‘the rebate model remains alive and well’ as the big three pharmacy benefit managers exclude around 600 drugs each from their formularies.
You may also be interested in...
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.
Rx Oversight Issues at Federal Workers’ Comp Program Endangered Patients, Audit Says
OWCP says that hiring a PBM will address overprescribing and cost concerns, but a consultant who participated in the audit is skeptical.
AHIP, PhRMA Try to Control Narrative as Heat on PBMs Intensifies
As health insurance lobby launches advertising campaign to defend ‘evidence-based, market-driven tools,’ drug firms point out the connection between insurers and pharmacy benefit managers.